PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10873157-5	2000	Expression of IL-6 and IL-8 was sensitive to SB203580, the specific inhibitor of p38 mitogen-activated protein (MAP) kinase and PD98059, an inhibitor of MAP kinase kinase.	SB 203580	45-53	interleukin 6	Homo sapiens	14-18	
10734320-6	2000	A pyrimidazole compound, SB203580, a specific inhibitor of p38 MAPK, inhibits production and gene expression of IL-6.	SB 203580	25-33	interleukin 6	Homo sapiens	112-116	
10727406-6	2000	Furthermore, inhibition of p38 kinase activity with the inhibitor SB203580 did not block STAT3 Ser(727) phosphorylation but rather increased both basal as well as IL-6-induced STAT3 transactivation, indicating that p38 may act as a negative regulator of IL-6-induced STAT3 transactivation through a presently unknown mechanism.	SB 203580	66-74	interleukin 6	Homo sapiens	163-167	
10727406-6	2000	Furthermore, inhibition of p38 kinase activity with the inhibitor SB203580 did not block STAT3 Ser(727) phosphorylation but rather increased both basal as well as IL-6-induced STAT3 transactivation, indicating that p38 may act as a negative regulator of IL-6-induced STAT3 transactivation through a presently unknown mechanism.	SB 203580	66-74	interleukin 6	Homo sapiens	254-258	
10734320-7	2000	SB203580 reduced significantly the stability of IL-6 mRNA.	SB 203580	0-8	interleukin 6	Homo sapiens	48-52	
10586114-7	1999	The IL-1-enhanced IL-6 protein secretion was strongly reduced by SB203580 and PD98059.	SB 203580	65-73	interleukin 6	Homo sapiens	18-22	
10620700-2	2000	Pretreatment of RSF with a specific p38 MAP kinase inhibitor, SB203580, blocked the induction of IL-6 and IL-8 without affecting nuclear translocation of nuclear factor kappaB (NF-kappaB) or IL-6 and IL-8 mRNA levels.	SB 203580	62-70	interleukin 6	Homo sapiens	97-101	
10504489-11	1999	The role of these activations in IL-6 production was confirmed by the ability of both inhibitors SB203580 (1 to 30 microM) and PD98059 (0.01 to 10 microM) to inhibit basal and TNF-alpha-stimulated IL-6 production in both cell types.	SB 203580	97-105	interleukin 6	Homo sapiens	33-37	
10534331-10	1999	Selective inhibition of either the p44/p42 MAPK pathway, by PD098059, or of the p38 MAPK pathway, by SB203580, blocked proliferation in response to IL-6.	SB 203580	101-109	interleukin 6	Homo sapiens	148-152	
10504489-11	1999	The role of these activations in IL-6 production was confirmed by the ability of both inhibitors SB203580 (1 to 30 microM) and PD98059 (0.01 to 10 microM) to inhibit basal and TNF-alpha-stimulated IL-6 production in both cell types.	SB 203580	97-105	interleukin 6	Homo sapiens	197-201	
10385244-10	1999	MK-571 mediated upregulation of IL-6 in the presence of IL-1 was partially attenuated by SB203580 and PD98059.	SB 203580	89-97	interleukin 6	Homo sapiens	32-36	
10358197-4	1999	IL-1-induced IL-6 production was also suppressed by SB203580.	SB 203580	52-60	interleukin 6	Homo sapiens	13-17	
9733787-4	1998	SB203580 concentration-dependently inhibited protein production and gene expression of IL-6 by human FLSs.	SB 203580	0-8	interleukin 6	Homo sapiens	87-91	
9832620-8	1998	SB203580, a specific inhibitor of p38 MAP kinase, significantly inhibited IL-1beta-induced IL-6 and stromelysin-1 production by both parental FLSs and MH7A cells; although PD098059, an inhibitor of the p42/p44 MAP kinase pathway, did not affect it.	SB 203580	0-8	interleukin 6	Homo sapiens	91-95	
9733787-6	1998	SB203580 significantly reduced the stability of IL-6 mRNA without affecting the rate of IL-6 gene transcription.	SB 203580	0-8	interleukin 6	Homo sapiens	48-52	
8617238-6	1996	Under the same conditions, SB203580 also completely inhibited TNF-induced synthesis of interleukin (IL)-6 and expression of a reporter gene that was driven by a minimal promoter containing two NF-Kappa B elements.	SB 203580	27-35	interleukin 6	Homo sapiens	87-105	
9452444-6	1998	We observed that the p38 mitogen-activated protein kinase (MAPK) inhibitor SB203580 was able to repress TNF-stimulated expression of the IL-6 gene, as well as of a kappaB-dependent reporter gene construct, without affecting the levels of NF-kappaB binding to DNA.	SB 203580	75-83	interleukin 6	Homo sapiens	137-141	
9120270-3	1997	SB 203580 significantly inhibited IL-1-stimulated IL-6, (30 to 50% at 1 microM) but not IL-8 production from human fibroblasts (gingival and dermal) and umbilical vein endothelial cells.	SB 203580	0-9	interleukin 6	Homo sapiens	50-54	
31322196-5	2019	The expression levels of interleukin (IL)-6, IL-8 and monocyte chemoattractant protein-1 increased following treatment with S100A8 and S100A9, and the increase was significantly blocked by specific signaling pathway inhibitors, including toll-like receptor 4 inhibitor (TLR4i), rottlerin, PD98059, SB203580 and BAY-11-7085.	SB 203580	298-306	interleukin 6	Homo sapiens	25-43	
34171447-10	2021	Moreover, inactivation of p38MAPK with specific inhibitor (SB203580) attenuated IL-6 induced NED of LNCaP cells.	SB 203580	59-67	interleukin 6	Homo sapiens	80-84	
34804428-15	2021	SB203580, PDTC, and alpha-LA reversed the effects of chemerin, reducing IL-6, TNF-alpha, NF-kappaB p-p65, and TGF-beta expression.	SB 203580	0-8	interleukin 6	Homo sapiens	72-76	
33355843-13	2021	On its own, SB203580 did not stimulate IL-6 secretion from HFCs; however, it dramatically suppressed the degree of IL-6 release stimulated by TNF-alpha from HFCs.	SB 203580	12-20	interleukin 6	Homo sapiens	115-119	
32500755-9	2021	RESULTS: Naringin or SB203580 pretreatment significantly suppressed the secretion of TNF-alpha and IL-6 induced by titanium particles in fibroblasts, while inhibition of ERK or JNK pathways showed no effect on production of TNF-alpha and IL-6.	SB 203580	21-29	interleukin 6	Homo sapiens	99-103	
32500755-9	2021	RESULTS: Naringin or SB203580 pretreatment significantly suppressed the secretion of TNF-alpha and IL-6 induced by titanium particles in fibroblasts, while inhibition of ERK or JNK pathways showed no effect on production of TNF-alpha and IL-6.	SB 203580	21-29	interleukin 6	Homo sapiens	238-242	
32069432-6	2020	MCP-1 and GM-CSF levels, as well as gene expressions of IL-6 and IL-8 in HTR8/SVneo cells were greatly increased by TNF-alpha (5, 10 and 20 ng/mL), but reversed by sevoflurane and SB203580.	SB 203580	180-188	interleukin 6	Homo sapiens	56-60	
34971958-10	2022	The p38 inhibitor SB203580 inhibited the secretion of IL-8, slightly inhibited the secretion of IL-6, and did not affect NF-kappaB activity.	SB 203580	18-26	interleukin 6	Homo sapiens	96-100	
33599317-13	2022	IL-6 induction was decreased by pretreatment of cells with NF-kappaB inhibitor SN50 or p38 MAPK inhibitor SB203580, while CCL2 induction was reduced by SN50 or JNK inhibitor SP600125.	SB 203580	106-114	interleukin 6	Homo sapiens	0-4	
33441226-5	2021	Then, in the 16HEB cells stimulated by STAT3 inhibitor Stattic or p38 MAPK inhibitor SB203580 in combination with HDM, the mRNA and protein expression levels of IL-6 and IL-8 were detected by qPCR and CBA.	SB 203580	85-93	interleukin 6	Homo sapiens	161-165	
33441226-8	2021	Interestingly, while SB203580 inhibited the activation of p38 MAPK signaling pathway, it only inhibited the mRNA levels of IL-6 and IL-8 in HDM-induced 16HBE cells, but had no effect on their protein levels.	SB 203580	21-29	interleukin 6	Homo sapiens	123-127	
29245047-6	2018	Conversely, pretreatment with SB203580, a selective inhibitor of p38 MAPK, blocked p38 MAPK phosphorylation and IL-6 and IL-8 expression.	SB 203580	30-38	interleukin 6	Homo sapiens	112-116	
30022772-7	2018	The gamma-irradiation-induced increase in IL-6 and IL-8 production was suppressed by apyrase (ecto-nucleotidase), NF157 (selective P2Y11 receptor antagonist) and SB203580 (p38 MAPK inhibitor).	SB 203580	162-170	interleukin 6	Homo sapiens	42-46	
30174670-10	2018	Both inhibition of p38 MAPK by SB203580 (10 microM) and knockdown of ER stress effector CCAAT-enhancer-binding protein homologous protein (CHOP) reduced gene and protein expression of IL-6 in Tg-treated cells.	SB 203580	31-39	interleukin 6	Homo sapiens	184-188	
30116631-11	2018	More importantly, the effect of MG132 on upregulating the levels of IL-6 was inhibited by SB203580, an inhibitor of P38 MAP kinases.	SB 203580	90-98	interleukin 6	Homo sapiens	68-72	
29193446-10	2018	p38MAPK inhibitor SB203580 reduced the development of senescence and IL-6 by TNF-alpha and LPS.	SB 203580	18-26	interleukin 6	Homo sapiens	69-73	
29412148-6	2018	A specific inhibitor of p38MAPK, SB203580 significantly decreased the secretion of IL-6 and IL-8, the major components of SASPs.	SB 203580	33-41	interleukin 6	Homo sapiens	83-87	
30404019-6	2019	ATP-induced IL-6 production was significantly inhibited by p38 inhibitors, SB203580, and doramapimod.	SB 203580	75-83	interleukin 6	Homo sapiens	12-16	
30404019-7	2019	Collagen type I production in SSc fibroblasts by ATP-induced IL-6/IL-6 receptor trans-signaling was inhibited by kaempferol and SB203580.	SB 203580	128-136	interleukin 6	Homo sapiens	61-65	
30838176-8	2019	In line with these results, ERK (U0126) and p38 MAPK (SB203580) specific signaling inhibitors suppressed hIL-6 expression and attenuated cell growth in PEL cells.	SB 203580	54-62	interleukin 6	Homo sapiens	105-110	
29061842-8	2018	Inhibition of p38 with SB203580 prevented IL-6 production, without altering permeability.	SB 203580	23-31	interleukin 6	Homo sapiens	42-46	
28465707-7	2017	The downmodulation of IL-6 by P. cicadae was inhibited by the p38 inhibitor (SB203580) or JNK inhibitor (SP600125).	SB 203580	77-85	interleukin 6	Homo sapiens	22-26	
28794655-10	2017	Further evidence indicated that P2Y12 and P2Y13 receptor-evoked increased gene expression of IL-1beta, IL-6 and TNF-alpha were inhibited by Y-27632 (ROCK inhibitor), SB203580 (P38MAPK inhibitor) and PDTC (NF-kappab inhibitor), respectively.	SB 203580	166-174	interleukin 6	Homo sapiens	103-107	
28794655-11	2017	Subsequently, P2Y12 and P2Y13 receptor-evoked release of IL-1beta, IL-6 and TNF-alpha, were also inhibited by Y-27632, SB203580 and PDTC, respectively.	SB 203580	119-127	interleukin 6	Homo sapiens	67-71	
28730070-8	2017	Various signal pathway inhibitors, including SP600125 (JNK inhibitor), SB203580 (p38 MAPK inhibitor) and BAY11-7082 (NF-kappaB inhibitor) significantly decreased the UVB-induced secretion of IL-6 and IL-8 secretion (P<0.05).	SB 203580	71-79	interleukin 6	Homo sapiens	191-195	
27650973-7	2016	NE-induced IL-6 was significantly inhibited by p38 inhibitor, SB203580, suggesting that NE-induced phosphorylation of p38 via ARbeta enhances IL-6 production in SSc fibroblasts.	SB 203580	62-70	interleukin 6	Homo sapiens	11-15	
27995982-10	2016	P38 inhibitor SB203580 suppressed IL-6 production, and inhibition of IL-6 receptor (IL-6R) activation by tocilizumab suppressed Fos expression.	SB 203580	14-22	interleukin 6	Homo sapiens	34-38	
27650973-7	2016	NE-induced IL-6 was significantly inhibited by p38 inhibitor, SB203580, suggesting that NE-induced phosphorylation of p38 via ARbeta enhances IL-6 production in SSc fibroblasts.	SB 203580	62-70	interleukin 6	Homo sapiens	142-146	
26915800-7	2016	We also found that the effects of APS on upregulating hepcidin and IL-6 expressions could be antagonized by pretreatment with SB203580, an inhibitor of p38 MAPK signaling.	SB 203580	126-134	interleukin 6	Homo sapiens	67-71	
27394658-6	2016	p38 and ERK1/2 MAPKs were involved in this effect, as indicated by the Cry1Ac-induced upregulation of CD80 and IL-6 and TNF-alpha abrogation by the p38 MAPK inhibitor SB203580.	SB 203580	167-175	interleukin 6	Homo sapiens	111-115	
25515776-9	2015	The production of IL6 and IL8 was also suppressed by p38 inhibitor SB203580.	SB 203580	67-75	interleukin 6	Homo sapiens	18-21	
25715004-7	2015	The latanoprost-induced release of IL-6, IL-8, and MCP-1 was attenuated by inhibitors of MAPK (PD98059, SB203580, or JNK inhibitor II) or NF-kappaB (IkappaB kinase 2 inhibitor) signaling pathways.	SB 203580	104-112	interleukin 6	Homo sapiens	35-39	
24995301-1	2014	The study was designed to determine the effects of peripheral injection of SB203580 on the synthesis of interleukin- (IL-) 1beta, IL-6, and tumor necrosis factor (TNF) alpha in the hypothalamus of ewes during prolonged inflammation.	SB 203580	75-83	interleukin 6	Homo sapiens	130-134	
25239226-6	2015	Induction of IL-6 production by IL-1beta was significantly reduced by addition of p38 MAPK (SB203580), MEK1/2 (U0126) or NF-kappaB (BAY11-7082) inhibitors, with the highest effect being observed with SB203580.	SB 203580	92-100	interleukin 6	Homo sapiens	13-17	
25239226-6	2015	Induction of IL-6 production by IL-1beta was significantly reduced by addition of p38 MAPK (SB203580), MEK1/2 (U0126) or NF-kappaB (BAY11-7082) inhibitors, with the highest effect being observed with SB203580.	SB 203580	200-208	interleukin 6	Homo sapiens	13-17	
25239226-8	2015	Results showed that IL-6 promoter activity of the parent pIL-6-Luc651 was significantly enhanced by IL-1beta, but the level was significantly attenuated by SB203580.	SB 203580	156-164	interleukin 6	Homo sapiens	20-24	
25849622-11	2015	IL-6 expression was more sensitive to inhibition of p38 (using SB203580) and was affected by Stattic in response to IL-17A/OSM stimulation.	SB 203580	63-71	interleukin 6	Homo sapiens	0-4	
24954857-12	2014	The p38-MAPK inhibitor SB203580 abolished the IL-6-induced WNT5A up-regulation and blocked IL-6-induced melanoma cell invasion.	SB 203580	23-31	interleukin 6	Homo sapiens	46-50	
24954857-12	2014	The p38-MAPK inhibitor SB203580 abolished the IL-6-induced WNT5A up-regulation and blocked IL-6-induced melanoma cell invasion.	SB 203580	23-31	interleukin 6	Homo sapiens	91-95	
24995301-3	2014	SB203580 is a selective ATP-competitive inhibitor of the p38 mitogen-activated protein kinase (MAPK), which is involved in the regulation of proinflammatory cytokines IL-1beta, IL-6 and TNFalpha synthesis.	SB 203580	0-8	interleukin 6	Homo sapiens	177-181	
24995301-4	2014	Intravenous injection of SB203580 successfully inhibited (P < 0.01) synthesis of IL-1beta and reduced (P < 0.01) the production of IL-6 in the hypothalamus.	SB 203580	25-33	interleukin 6	Homo sapiens	137-141	
21176394-7	2011	The IL-6 secretory pathway of MSCs was inhibited by SB203580, an inhibitor of p38 MAPK or siRNA against p38 MAPK, suggesting IL-6 secretion by MSCs is mediated through the activation of p38 MAPK.	SB 203580	52-60	interleukin 6	Homo sapiens	4-8	
23219088-6	2013	UVB-induced production of IL-6 was inhibited by SB203580, a p38 MAPK inhibitor.	SB 203580	48-56	interleukin 6	Homo sapiens	26-30	
23232207-8	2013	CAP-induced time dependent changes in the phosphorylation status of mitogen activated protein kinase (MAPK) signaling mediators that led to a 2.5-fold increase in IL-6 release after 24 h. This rise did not occur either in TRPV1 siRNA gene silenced cells or during exposure to SB203580 (10 muM), a selective p38 MAPK inhibitor.	SB 203580	276-284	interleukin 6	Homo sapiens	163-167	
21161531-6	2012	Furthermore, IL-6 and IL-8 expression was quantified by real-time polymerase chain reaction (RT-PCR) and ELISAs from cells which were exposed to SB203580, U0126 and NaHS and stimulated by IL-1beta.	SB 203580	145-153	interleukin 6	Homo sapiens	13-17	
22110547-7	2012	In addition, EBNE-induced production of IL-6 and VEGF was inhibited by PD98059 (a p44/42 MAPK inhibitor), SB203580 (a p38 MAPK inhibitor), and PDTC (a NF-kappaB inhibitor), but not SP600125 (a JNK inhibitor).	SB 203580	106-114	interleukin 6	Homo sapiens	40-44	
22129063-6	2011	U0126 (MAPK kinase (MEK)1/2 inhibitor) and SB203580 (p38 MAPK inhibitor) decreased the LPS-enhanced release of IL-6 and GM-CSF.	SB 203580	43-51	interleukin 6	Homo sapiens	111-115	
21288261-5	2011	Using two potent and selective inhibitors of MEK activation by Raf-1 (PD-098059) and p38 (SB-203580), it was also demonstrated that both ERK1/2 and p38 pathways play key roles in the production of IL-6 as well as in ICAM-1, VCAM-1 and E-selectin expression by Hib porin.	SB 203580	90-99	interleukin 6	Homo sapiens	197-201	
21176394-7	2011	The IL-6 secretory pathway of MSCs was inhibited by SB203580, an inhibitor of p38 MAPK or siRNA against p38 MAPK, suggesting IL-6 secretion by MSCs is mediated through the activation of p38 MAPK.	SB 203580	52-60	interleukin 6	Homo sapiens	125-129	
20631726-6	2010	EGFP-LEDGF-HaCaT cells had increased expression of IL-6, which was attenuated by LEDGF-specific RNA interference and the p38-specific inhibitors SB-239063 and SB-203580.	SB 203580	159-168	interleukin 6	Homo sapiens	51-55	
24302816-7	2013	Furthermore, both NF- kappa B inhibitor Bay11-7085 and p38 inhibitor SB203580 significantly suppressed the enhanced production of IL-6 and MMPs induced by HMGB1-LPS.	SB 203580	69-77	interleukin 6	Homo sapiens	130-134	
21979577-8	2012	SB203580 inhibited ATP-induced TNF-alpha, IL-6, and NO production.	SB 203580	0-8	interleukin 6	Homo sapiens	42-46	
22605923-6	2012	Pretreatment with 10(-10) M 17-beta-estradiol greatly inhibited the increased expression and production of IL-6, IL-1, and TNF-alpha induced by hyperosmolarity, whereas with the administration of SB203580 (10 muM), an inhibitor of the p38 pathway, the inhibiting effect of 17-beta-estradiol disappeared.	SB 203580	196-204	interleukin 6	Homo sapiens	107-111	
20739465-10	2011	Hypertonicity-induced increases in IL-6 and IL-8 releases were suppressed by exposure to capsazepine, AG 1478, ERK inhibitor PD 98059, p38 inhibitor SB 203580, or NF-kappaB inhibitor PDTC.	SB 203580	149-158	interleukin 6	Homo sapiens	35-39	
19656660-12	2009	Distinctly, pharmacological inhibition of p38 MAPK with SB203580 was associated with transcriptional down-regulation of COX-2 and MMP-13 in the IL-1beta- or PMA-treated HSF cells.	SB 203580	56-64	interleukin 6	Homo sapiens	169-172	
20351184-6	2010	The NF-kappaB pathway inhibitor BAY-11, JNK inhibitor JNKi II, and p38 inhibitor SB203580 suppressed the synergistic effect of IL-6 and IL-17 on IL-6 expression.	SB 203580	81-89	interleukin 6	Homo sapiens	127-131	
20351184-6	2010	The NF-kappaB pathway inhibitor BAY-11, JNK inhibitor JNKi II, and p38 inhibitor SB203580 suppressed the synergistic effect of IL-6 and IL-17 on IL-6 expression.	SB 203580	81-89	interleukin 6	Homo sapiens	145-149	
19931737-8	2009	The p38 inhibitor SB203580, by blocking nuclear factor-kappaB (NF-kappaB) activation, prevented both the transcriptional and translational regulation of radiation-induced IL-6 expression.	SB 203580	18-26	interleukin 6	Homo sapiens	171-175	
18825409-9	2009	Pretreatment of cells with SB203580 (inhibitor of p38) and PD98059 (inhibitor of ERK) attenuated LPS-induced IL-6 expression, whereas LY294002 (inhibitor of PI3K) markedly amplified the LPS-stimulated synthesis of IL-6.	SB 203580	27-35	interleukin 6	Homo sapiens	109-113	
19576293-10	2009	As intracellular signalling pathway we could demonstrate that SB203580 as specific p38 inhibitor most effectively down regulated the unwanted IL-6 release after cooling and rewarming.	SB 203580	62-70	interleukin 6	Homo sapiens	142-146	
18825409-9	2009	Pretreatment of cells with SB203580 (inhibitor of p38) and PD98059 (inhibitor of ERK) attenuated LPS-induced IL-6 expression, whereas LY294002 (inhibitor of PI3K) markedly amplified the LPS-stimulated synthesis of IL-6.	SB 203580	27-35	interleukin 6	Homo sapiens	214-218	
19249598-5	2009	A p38 mitogen-activated protein kinase inhibitor, SB203580, also inhibited the increase in IL-6 messenger RNA levels.	SB 203580	50-58	interleukin 6	Homo sapiens	91-95	
18457971-5	2008	p38 MAPK inhibitor SB203580 suppressed interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) release, as well as the activation of cPLA(2).	SB 203580	19-27	interleukin 6	Homo sapiens	72-85	
19494504-11	2009	Eotaxin-induced production of IL-1beta, IL-6, and MIP-1beta was significantly reduced by the MEK inhibitor PD98059, p38 MAPK inhibitor SB203580, or PI3K inhibitor LY294002.	SB 203580	135-143	interleukin 6	Homo sapiens	40-44	
18457971-5	2008	p38 MAPK inhibitor SB203580 suppressed interleukin-1beta (IL-1beta) and interleukin-6 (IL-6) release, as well as the activation of cPLA(2).	SB 203580	19-27	interleukin 6	Homo sapiens	87-91	
18457971-8	2008	As a downstream enzyme of cPLA(2), cyclooxygenase-2 (COX-2) was down-regulated by SB203580 and/or AACOCF(3), which precisely matched the levels of IL-1beta and IL-6.	SB 203580	82-90	interleukin 6	Homo sapiens	160-164	
17724435-10	2008	SB203580 also prevented the CytoMix-induced permeability increase and reduced NO, IL-6, and IL-8 levels.	SB 203580	0-8	interleukin 6	Homo sapiens	82-86	
18093851-6	2008	SB-203580 caused dose-dependent decreases in cytokine protein expression and decreased IL-6 and IL-11 mRNA expression.	SB 203580	0-9	interleukin 6	Homo sapiens	87-91	
18292576-8	2008	SB203580 inhibited the phosphorylation of c-Fos enhanced by IL-1 plus IL-6, and diminished expression of the CRP gene.	SB 203580	0-8	interleukin 6	Homo sapiens	70-74	
18177344-6	2008	However, p38 inhibitor SB203580 abrogated TNF-alpha, IL-1beta and IL-6 production.	SB 203580	23-31	interleukin 6	Homo sapiens	66-70	
17637508-11	2007	AG490 as well as SB 203580 and parthenolide blocked CT-1 induced IL-6 expression completely.	SB 203580	17-26	interleukin 6	Homo sapiens	65-69	
17845838-4	2008	We found that pre-treatment of microglial cells with a p38-inhibitor (SB203580) prevented Mn+LPS-induced production of IL-6 and TNF-alpha.	SB 203580	70-78	interleukin 6	Homo sapiens	119-123	
17876544-10	2007	Inhibitors for ERK (PD98059 and U0216) and p38 MAPK (SB203580) significantly reduced the IL-17F-induced IL-6, IL-8, LIF, MMP-1, and MMP-3 secretion.	SB 203580	53-61	interleukin 6	Homo sapiens	104-108	
17207362-4	2007	RESULTS: SB203580 obviously down-regulated the activities of p38 and cPLA(2), as well as the release of IL-1 beta and IL-6.	SB 203580	9-17	interleukin 6	Homo sapiens	118-122	
17196171-5	2007	Furthermore, IL-6 secretion by PC-3 and DU145 cells was significantly suppressed by SAPKs inhibitor, especially by p38MAPK inhibitor SB203580, but not by JNK inhibitor SP600125 nor by MEK inhibitor, PD98059.	SB 203580	133-141	interleukin 6	Homo sapiens	13-17	
17849265-5	2007	When added to MG-63 cells, IL-6 stimulated the production of cathepsin B, which was reduced significantly by the addition of SB203580, a specific p38 MAPK inhibitor.	SB 203580	125-133	interleukin 6	Homo sapiens	27-31	
17849265-10	2007	Moreover, IL-6 increased the activity of urokinase type plasminogen activator (uPA) in MG-63 cells, which was inhibited by SB203580, PDTC and NF-kappaB SN50.	SB 203580	123-131	interleukin 6	Homo sapiens	10-14	
17197193-11	2006	AG490, SB203580, piceatannol, parthenolide and cycloheximide inhibit CT-1 induced IL-6 mRNA and protein expression whereas wortmannin and PD98059 did not inhibit IL-6 expression.	SB 203580	7-15	interleukin 6	Homo sapiens	82-86	
16532021-6	2006	The p38 inhibitor SB203580 and the PKC inhibitors Calphostin C and Go6976 completely inhibited IL-1-induced IL-6 production.	SB 203580	18-26	interleukin 6	Homo sapiens	108-112	
16197469-7	2005	NF-kappaB inhibitor BAY 11-7082 and p38 MAPK inhibitor SB 203580 significantly decreased IL-6 release in a co-culture of BEAS-2B cells and eosinophils.	SB 203580	55-64	interleukin 6	Homo sapiens	89-93	
15917303-5	2005	Pretreatment with the pharmacological inhibitors of p38 MAPK SB-203580 or SB-202190 blocked IL-6-induced SGK phosphorylation at Ser78 and SGK activation.	SB 203580	61-70	interleukin 6	Homo sapiens	92-96	
15913932-6	2005	SB203580 inhibited the expression of IL-6 mRNA.	SB 203580	0-8	interleukin 6	Homo sapiens	37-41	
15894558-8	2005	SB-203580, a p38 MAPK-specific inhibitor, inhibits IL-6-induced p38 MAPK phosphorylating activity and suppresses IL-6-stimulated cell proliferation.	SB 203580	0-9	interleukin 6	Homo sapiens	51-55	
15894558-8	2005	SB-203580, a p38 MAPK-specific inhibitor, inhibits IL-6-induced p38 MAPK phosphorylating activity and suppresses IL-6-stimulated cell proliferation.	SB 203580	0-9	interleukin 6	Homo sapiens	113-117	
15913932-5	2005	Increased IL-6 by DFX was significantly inhibited by p38 inhibitor, SB203580 (about 72% inhibition, P=0.027) but not ERK inhibitor, PD98059 or JNK inhibitor, SP600125.	SB 203580	68-76	interleukin 6	Homo sapiens	10-14	
16435581-2	2005	When added to HGFs, IL-1beta had a stimulatory effect on the production of IL-6, and this effect was significantly reduced by SB203580, a specific p38 MAPK inhibitor.	SB 203580	126-134	interleukin 6	Homo sapiens	75-79	
15796767-9	2005	The LPS-induced IL-6 production was blocked by the specific p38alphaMAP kinase inhibitor, SB203580, and by the synthetic glucocorticoid, dexamethasone.	SB 203580	90-98	interleukin 6	Homo sapiens	16-20	
16435581-4	2005	Both the NF-kappaB inhibitors in the presence of SB203580 had more inhibitory effect on IL-6 release.	SB 203580	49-57	interleukin 6	Homo sapiens	88-92	
14998552-7	2004	SB203580 and PD98059 decreased LPS-induced gene expression of IL-1beta and IL-6.	SB 203580	0-8	interleukin 6	Homo sapiens	75-79	
15345683-11	2004	The addition of SB203580 to ionomycin decreased (P<0.05) nuclear p-p38 MAPK and totally abolished (P<0.05) the ionomycin- induced increase in IL-6 mRNA.	SB 203580	16-24	interleukin 6	Homo sapiens	148-152	
15251176-9	2004	When cells exposed to 200 microM SM were treated with the p38 MAP kinase inhibitor SB203580, the levels of IL-8, IL-6, and TNF-alpha and IL-1beta were significantly decreased when compared with cells that were untreated.	SB 203580	83-91	interleukin 6	Homo sapiens	113-117	
15345332-6	2004	Furthermore, both SB203580 (an inhibitor of p38 mitogen-activated protein kinase [MAPK]) and PD98059 (an inhibitor of MEK, upstream of ERK) attenuated the BK-induced IL-6 and PGE(2) synthesis.	SB 203580	18-26	interleukin 6	Homo sapiens	166-170	
15117678-6	2004	Expression of IL-1beta, IL-6, IL-8, and COX-2 mRNA was reduced by 30 microM PP1, an Src family tyrosine kinase inhibitor, and by 25 microM SB-203580, a p38 MAPK inhibitor.	SB 203580	139-148	interleukin 6	Homo sapiens	24-28	
14565941-9	2004	Activation of p38 MAPK was also seen in cocultures by Western blot, whereas IL-6 production in cocultures was significantly inhibited by the p38 inhibitor SB203580.	SB 203580	155-163	interleukin 6	Homo sapiens	76-80	
12637577-2	2003	Here we show unequivocally that the production of interleukin (IL)-1beta, IL-6, IL-10, and tumor necrosis factor alpha (TNFalpha) requires p38 MAPK activity by demonstrating that the inhibitory effects of SB 203580 were reversed by expression of an SB 203580-resistant form of p38alpha (SBR-p38alpha) that fails to bind to SB 203580.	SB 203580	205-214	interleukin 6	Homo sapiens	74-78	
12853969-6	2003	IL-6 activation by TGF-beta1 was accompanied by nuclear translocation of NF-kappaB, which was blocked by the p38 inhibitors SB202190 and SB203580 or by IkappaBalphaDeltaN transfection, indicating the crucial role for the p38-NF-kappaB signaling in TGF-beta1 induction of IL-6.	SB 203580	137-145	interleukin 6	Homo sapiens	0-4	
12505790-3	2003	Treatment with the p38 inhibitor SB-203580, the MEK1 and MEK2 inhibitor U-0126, or the translational inhibitor cycloheximide inhibited the induction of C/EBP beta and IL-6 by IFN-gamma, whereas the MEK1 inhibitor PD-98059 or the tyrosine kinase inhibitor genistein had no effect.	SB 203580	33-42	interleukin 6	Homo sapiens	167-171	
12145097-7	2002	SB203580 decreased IL-6 production and gene expression, but PD98059 had no effect on IL-6 production and gene expression.	SB 203580	0-8	interleukin 6	Homo sapiens	19-23	
12594059-8	2003	Blocking ERK1/2 with PD98059 or p38 MAPK with SB203580 reduced BK-induced IL-6 expression.	SB 203580	46-54	interleukin 6	Homo sapiens	74-78	
11165942-2	2001	When added to MG-63 cells, tumor necrosis factor-alpha (TNF-alpha) had a stimulatory effect on the production of IL-6, and this elevation was significantly reduced by SB203580, a specific p38 MAPK inhibitor.	SB 203580	167-175	interleukin 6	Homo sapiens	113-117	
12137744-5	2002	The inhibitors SB203580, PD98059, SN50, cycloheximide and D-ribofuranosylbenzimidazole each reduced the basal and TNFalpha-stimulated secretion of IL-1beta and also reduced IL-6 secretion with the exception of SN50.	SB 203580	15-23	interleukin 6	Homo sapiens	173-177	
12016129-9	2002	MAPK inhibitors (SB-203580, PD-98059, and U-0126) significantly reduced the IL-17-induced IL-6 and chemokine secretion.	SB 203580	17-26	interleukin 6	Homo sapiens	90-94	
11231289-3	2001	Pharmacologic inhibition of either the ERK or the p38 MAPK pathway, using U0126 and SB203580, respectively, reduced interleukin-6 protein induction by at least 70%, and combined inhibition of both pathways fully blocked interleukin-6 protein expression and reduced interleukin-6 mRNA induction by more than 80%.	SB 203580	84-92	interleukin 6	Homo sapiens	116-129	
11401420-4	2001	The p38 MAPK pathway is specifically involved in the combined agents-induced NO and IL-6 release, since NO and IL-6 release in the presence of a specific inhibitor of p38 MAPK, 4-(4-fluorophenyl)-2-(4-metylsulfinylphenyl)-5-(4-pyridyl)imidazole (SB203580), are significantly diminished.	SB 203580	246-254	interleukin 6	Homo sapiens	84-88	
12020969-6	2002	Interestingly, SB203580 reduced the mRNA expression for iNOS, TNFalpha, and IL-6, indicating inhibition prior to translation.	SB 203580	15-23	interleukin 6	Homo sapiens	76-80	
12008923-4	2002	The p38 inhibitor SB 203580 also suppressed their IL-6 production-inducing activities, whereas the ERK1/2-activating MAPK kinase (MEK1) inhibitor PD 98059 did not suppress their activities.	SB 203580	18-27	interleukin 6	Homo sapiens	50-54	
11747626-6	2001	In human osteoblasts (SaM-1 cells) treated with 10 microg/ml LPS, increases in IL-6 mRNA and synthesis were inhibited by anti-CD14 antibody (MEM-18), PD98059 (an inhibitor of classic mitogen-activated protein kinase [MAPK]), or SB203580 (an inhibitor of p38 MAPK) but were not inhibited by H-89 (an inhibitor of protein kinase A [PKA]) and calphostin C (an inhibitor of protein kinase C [PKC]).	SB 203580	228-236	interleukin 6	Homo sapiens	79-83	
11597988-8	2001	PD98059 and SB203580 inhibited Ang II-induced IL-6 expression.	SB 203580	12-20	interleukin 6	Homo sapiens	46-50	
11562425-3	2001	Pretreatment of ASM cells with SB203580, a p38 MAPK inhibitor, slightly enhanced TNF alpha-induced ICAM-1 expression in a dose-dependent manner but partially inhibited secretion of RANTES and IL-6.	SB 203580	31-39	interleukin 6	Homo sapiens	192-196	
11319753-5	2001	SB 203580, a selective inhibitor of p38 MAPK, inhibited IL-1 and TNF-induced p38 MAPK activity and IL-6 production (IC(50)s 0.3--0.5 microM) in osteoblasts and chondrocytes.	SB 203580	0-9	interleukin 6	Homo sapiens	99-103	
11165942-4	2001	Both the NF-kappaB inhibitors in the presence of SB203580 had a more inhibitory effect on IL-6 release.	SB 203580	49-57	interleukin 6	Homo sapiens	90-94	
11028659-8	2000	Furthermore, PD98059 or SB203580 significantly suppressed BK-induced IL-6 and IL-8 production and their gene expression.	SB 203580	24-32	interleukin 6	Homo sapiens	69-73	
12760489-2	2001	When added to cultures of cardiomyocytes, the combined agents (LPS/IFN-gamma or TNF-alpha/IFN-gamma) had stimulatory effect on the production of IL-6 and the elevation was significantly reduced by SB203580, a specific p38 MAPK inhibitor.	SB 203580	197-205	interleukin 6	Homo sapiens	145-149	
12760489-3	2001	SB203580 inhibited protein production and gene expression of IL-6 in a concentration-dependent manner.	SB 203580	0-8	interleukin 6	Homo sapiens	61-65